

1 **Instruments for the identification of patients in need of palliative care: a systematic review protocol of**
 2 **measurement properties**

3 **Abstract**

4 **Objective:** to provide a comprehensive overview of the psychometric properties of available clinician-
 5 reported instruments developed to identify patients in need of general and specialized palliative care in
 6 acute care settings.

7 **Introduction:** Identification of patients in need of palliative care has been recognized as an area where
 8 many healthcare professionals need guidance. Differentiating between patients who require general
 9 palliative care and patients with more complex conditions who need specialized palliative care is
 10 particularly challenging. To our knowledge, no instrument are available to date to assist healthcare
 11 professionals to make this identification.

12 **Inclusion criteria:** Will be included studies reporting : i) instruments aiming to identify patients in need
 13 of PC, ii) sample of adult patients in need of PC in acute care settings, iii) Clinician-reported outcome
 14 measures (ClinROMs), iv) the development process or one or more of its measurement properties. Will
 15 be excluded studies conducted intensive care units, emergency departments, and nursing homes.

16 **Methods:** We will search studies published in English and French in: Embase.com, Medline Ovid SP,
 17 Pubmed, and CINAHL EBSCO and other sources, such as Google Scholar, government websites, and
 18 hospice websites. All citations will be screened and selected by two independent reviewers. Data
 19 extraction, quality assessment, and syntheses of included studies will be performed according to the
 20 COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) criteria.

21 PROSPERO systematic review registration number: CDR42020150074.

22 **Keywords:** Identification; palliative care; measurement properties; instruments.
 23

24 Introduction

25 Patients in need of palliative care (PC) are present in all different care settings. Prevalence varies from
26 9% to 73% in acute care settings depending on pathologies, co-morbidities or frailty.¹⁻⁵ An international
27 prevalence study revealed that the proportion of individuals who died from diseases indicating a need
28 for palliative care ranged from 38% to 74%.⁶ According to Murtagh et al.,⁷ 63% to 82% of the population
29 will need palliative care at some point of their disease trajectory. With the increase of the ageing
30 population and the number of patients suffering from chronic diseases and polymorbidity, the number
31 of patients in need of PC is likely to increase further.

32 When patients do not receive appropriate PC, there is strong evidence of (i) excess hospital mortality -
33 80% - while the majority of people wish to die at home;⁸⁻¹¹ (ii) suboptimal symptom management;¹²⁻¹⁴
34 (iii) unplanned hospitalizations with longer hospital stays;¹⁵⁻¹⁶ (iv) prescription of inappropriate
35 treatments due to a lack of anticipative care plans,¹⁷⁻¹⁸ and (v) insufficient support for the patient and
36 their relatives.^{15, 19-20} Out of all patients in need of PC, about 75% to 80% of them can be cared by non-
37 specialist teams (general PC) and the remaining 20%-25%, may need specialized PC provided by PC
38 specialists due to the complexity of their conditions.²¹⁻²³ There is an internationally recognized distinction
39 between patients requiring "general" versus "specialized" palliative care. General PC are provided by
40 non-specialized professionals for situations without any element of complexity. Specialized PC are for
41 patients whose illness is characterized by great clinical instability and/or a high level of psycho-socio-
42 existential suffering, making their situation complex to the point, where non-specialist in PC do not have
43 the necessary competences to care for them.^{8, 12}

44 Identification of patients in need of general or specialized PC is a pre-requisite for appropriate
45 management.²⁴ However, adequate identification is challenging as it relies on an unclear World Health
46 Organization (WHO) definition which defines PC as "an approach that improves the quality of life of
47 patients and their families facing the problem associated with life-threatening illness, through the
48 prevention and relief of suffering by means of early identification and impeccable assessment and
49 treatment of pain and other problems, physical, psychosocial and spiritual".^{25[para.1]} This definition does
50 not allow differentiating between general and specialized PC.²⁶⁻²⁹ Despite this, experts agree with PC
51 not being exclusively associated with terminal care and not depending only on patient diagnosis or
52 prognosis, but also on patients' needs. They confirm that PC should be initiated early in a patient
53 disease trajectory.³⁰ The identification of patients in need of PC without a valid tool is sub-optimal
54 because it occurs mostly at the end of life or only for highly complex situations.

55 A growing number of instruments exists to help professionals identifying patients in need of PC. These
56 instruments include criteria concerning the severity of illness, the progression of the disease, and its
57 associated frailty. Some instruments were designed only for a specific setting, such as the emergency
58 department or intensive care.³¹ Although, it is recommended to integrate palliative care early in the
59 stage of a life-threatening event, treatment goal of patients who require intensive care, is primarily to
60 sustain vital functions. Instruments designed for PC patients may therefore not be appropriate for this

61 population. Other instruments were designed for a specific pathology, for example interstitial lung
62 disease,³² or for a specific age group such as older people.³³ Others were designed for general use.³⁴⁻
63 ³⁶

64 To implement such an instrument into daily practice it is necessary to select the most suitable one
65 based on its psychometric properties, particularly validity (measure what it is supposed to measure),
66 reliability (consistency), and responsiveness (ability to detect change over time).

67 In palliative care, many patients are not able to fill in a patient-reported outcome to evaluate their own
68 palliative care needs. For example patients with dementia, any cognitive impairment or delirium, and
69 those who are not well informed about the stage of their disease, or who have some cultural barriers to
70 discuss this topic. In this context, it seems important that healthcare professionals carry out this first
71 screening, which will assist them to engage in discussion with the patient and her/his relatives about
72 the disease trajectory and their needs, and to give them the most appropriate care. The focus of this
73 review is therefore on clinician-reported outcome measures (ClinROMs) for the identification of patients
74 in need of PC.

75 A preliminary search of MEDLINE, the Cochrane Database of Systematic Reviews, the COSMIN
76 database, and the JBI Database of Systematic Reviews and Implementation Reports was conducted
77 and two systematic reviews on the topic were identified.³⁷⁻³⁸ Both reviews are focused on the inventory
78 and the description of the available instruments.

79 Maas et al. completed their systematic review by a survey conducted with European general
80 practitioners (GPs) to identify non published instruments.³⁷ They carried out their review in only two
81 databases (PubMed/MEDLINE and Embase) and they focused their searching on articles describing
82 identification instruments suitable for use in primary care. A narrative approach was used to synthesize
83 data. Then they compared the content of the different instruments and the identification criteria. Few or
84 no information are available about the data collection process, the quality assessment of the studies,
85 the studies' characteristics and whether authors have been contacted to obtain complementary data.
86 They found five articles, which described four different instruments. These instruments are: the
87 RADbout indicators for Palliative Care needs (RADPAC),³⁹ the Residential home palliative care tool,⁴⁰
88 the Supportive and Palliative Care Indicators Tool (SPICT)³⁵ and the Early identification tool for
89 palliative care patients.⁴¹ The complementary survey allowed finding three instruments which had not
90 been identified in the literature although two of them are widely known, which raises questions about
91 the quality of the review. These three instruments are: the Prognostic Indicator Guide of the UK-based
92 Gold Standard Framework (PIG-GSF),³⁴ the NECPAL-CCOMS-ICO³⁶ and the Quick guide.⁴² Then
93 instruments were compared. When sensitivity and specificity were reported in the original studies, the
94 authors of this review mentioned them, but without mentioning any psychometric assessment. None of
95 the presented instruments distinguishes patients in need of general vs. specialized PC.

96 Walsh et al. realized their systematic review following the Preferred Reporting Items for Systematic
97 Review and Meta-Analysis (PRISMA).^{38,43} Most of the PRISMA criteria are presented but they did not
98 perform any systematic evaluation of the psychometric properties and risks of bias. They used a
99 deductive approach to analyze the content of four instruments to determine the usability and
100 acceptability in clinical practice. These four instruments are: the Prognostic Indicator Guide of the UK-
101 based Gold Standard Framework (PIG-GSF),³⁴ the NECPAL-CCOMS-ICO;³⁶ the SPICT³⁵ and the
102 RADPAC.³⁹ They concluded that there is limited evidence these instruments appropriately identify
103 patients in need of PC early in their illness trajectory. None of the presented instruments distinguishes
104 patients in need of general vs. specialized PC.

105 In conclusion, neither of these two reviews included a systematic appraisal of the psychometric
106 properties of the selected instruments. This justifies the necessity to perform a new systematic review
107 with the following aim: to provide a comprehensive overview of the psychometric properties of available
108 clinician-reported instruments developed to identify patients in need of palliative care regardless of the
109 care setting – except for intensive care units and emergency departments.

110 Review Question

111 The question of this review is: what are the measurement properties of instruments that allow the
112 identification of adult patients in need of palliative care and that can be used in all acute care settings
113 except for emergency and intensive care units?

114 Inclusion Criteria

115 The COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments)
116 guidelines for systematic reviews of measurement properties recommend the following criteria of
117 inclusion:⁴⁴ i) the instrument should aim to measure the construct of interest (identification of patients
118 in need of PC), ii) the study sample should concern the target population of interest (adult patients in
119 need of PC), iii) the study should concern the type of measurement instrument of interest (ClinROMs),
120 iv) the aim of the study should be the development of a measurement instrument or the evaluation of
121 one or more of its measurement properties.

122 Population

123 This review will consider studies including adult patients with life limiting cancer or non-cancer illness
124 (e.g. chronic, progressive, incurable illness likely to cause death), in palliative care or in end of life care
125 situation. Patients will need to be hospitalized in any acute care settings, except intensive care units,
126 emergency departments and nursing home.

127 Instrument and construct

128 This review will consider studies presenting any measurement property of clinician-reported outcome
 129 measurement (ClinROMs), allowing the identification of patients in need of generalized or specialized
 130 palliative care (construct of interest). As those instruments have to be used by others professionals than
 131 physicians, we will include instruments comprising general indicators of decline and frailty (e.g. , but
 132 exclude biological markers that require specific investigation or exam (e.g. serum albumin). Due to the
 133 necessity to identify patients in need of PC as early as possible, prognostic instrument will be excluded.

134 Inclusion criteria: palliative care, adult patient (>18yrs), all pathologies (cancer/non-cancer), acute care
 135 settings, instruments/tools for identification, studies reporting the development of instruments or one or
 136 more measurement properties of instruments: content validity, reliability, responsiveness.

137 Exclusion criteria: disabled persons, intensive care, emergency, nursing homes, caregivers, pediatric
 138 patients, neonates, prognosis instrument, surprise question only, biomarkers, instrument used as an
 139 outcome measurement with no measurement properties reported.

140 Outcomes

141 The outcomes will include the measurement properties of the assessed instruments. They refer to the
 142 psychometric properties of the identification instruments.

143 The COnsensus-based Standards for the selection of health status Measurement INstruments
 144 (COSMIN) propose a guideline for systematic reviews of measurement properties for patient-reported
 145 outcome measures (PROMs).⁴⁴ As this guideline designed for PROMs include criteria that are not
 146 relevant for ClinROMs (e.g. box 2a-2c content validity), only the relevant criteria will be used in this
 147 review. The following 10 steps recommendations and instruments will be used. Steps 1 to 4 are
 148 standard procedures when performing systematic reviews. Steps 5 to 7 concern the evaluation of the
 149 measurement properties of the included instrument. Steps 8 to 10 concern the evaluation of the
 150 interpretability and feasibility of the instruments and the reporting of the instruments included in the
 151 systematic review. The COSMIN Risk of bias checklist will be followed.⁴⁵ This review will focus on the
 152 development of instruments and mainly on their measures of validity and reliability.

153 The development of instruments is evaluated through questions about the construct, the target
 154 population, the context of use, the item generation, the data analyses, the comprehensibility and
 155 comprehensiveness, as well as how the instrument was tested.⁴⁶

156 Psychometric properties of the instruments are assessed through several types of validity. For this
 157 review, the COSMIN group taxonomy measurement will be used.

158 Measures of validity refer to the degree to which an instrument measures the construct it has to
 159 measure. They include:

- 160 • content validity: the degree to which the content of an instrument is an adequate reflection of
161 the construct to be measured, including face validity. Content validity is evaluated by relevant
162 items for the construct, the target population, the comprehensiveness of the instrument and by
163 the Content Validity Index (CVI).
- 164 • construct validity: the degree to which the scores of an instrument are consistent with
165 hypotheses based on the assumption that the instrument measures the construct to be
166 measured. It also includes the structural validity, in other words the degree to which an
167 instrument adequately captures the dimensionality of the construct that must be measured.
168 Construct validity is evaluated by factor analysis.
- 169 • criterion validity: the degree to which the scores of an instrument are an adequate reflection of
170 a 'gold standard' criterion.⁴⁵ Criterion validity is evaluated by the correlation with the gold
171 standard and will only be considered if the gold-standard is in accordance with COSMIN
172 guidelines.⁴⁴

173 Measures of reliability refer to the extent to which scores for patients who have not changed are the
174 same for repeated measurement under several conditions. They include:

- 175 • internal consistency: the degree of the interrelatedness among the items. It is measured by
176 Cronbach's alpha or KR-20.
- 177 • reliability: the proportion of the total variance in the measurements which is due to 'true'
178 differences between patients. It is assessed by intra-class correlation coefficients (ICC),
179 weighted or un-weighted Kappa statistics and standard error of measurement (SEM).
- 180 • measurement error: the systematic and random error of a patient's score that is not attributable
181 to true changes. It is measured by the Standard Error of Measurement (SEM), Smallest
182 Detectable Change (SDC), Limits of Agreement (LoA) or a percentage of agreement.⁴⁵

183 When applicable, responsiveness – the ability to detect change over time in the construct to be
184 measured - will be assessed using the following criteria: absolute or relative correlations or differences
185 of the change scores, area under the Receiver Operating Curve (ROC), or sensitivity and specificity.

186 Types of studies

187 Any quantitative study design will be considered for inclusion in this systematic review of measurement
188 properties; however, the included studies will be those that report on the development and/or validation
189 of measurement instruments as described above. Studies published in English and French – authors'
190 commonly spoken languages - will be included.

191 **Methods**

192 The proposed systematic review will be conducted in accordance with the COSMIN methodology for
193 systematic reviews of measurement properties for PROMs.⁴⁷ The title has been registered on the JBI

194 registry. All the documents that will be used for this review are on the COSMIN website:
 195 <https://www.cosmin.nl/cosmin-tools/>.

196 Search strategy

197 The search strategy will aim to locate published and unpublished studies. It will be based on the
 198 COSMIN recommendations and using the precise search filter for measurement properties to capture
 199 relevant measurement properties.⁴⁸ The systematic literature search will be performed in collaboration
 200 with a librarian. An initial limited search of MEDLINE and CINAHL will be conducted, followed by an
 201 analysis of text words contained in the title and abstract, and of the index terms used to describe the
 202 article. The search strategies will be adapted to the syntax and subject headings of each database. An
 203 example for a draft strategy in Medline Ovid SP is provided in Appendix I. The search will be conducted
 204 in four electronic bibliographic databases without date restrictions.

205 Information sources

206 The bibliographic databases to be searched will include Embase.com, Medline Ovid SP, Pubmed (NOT
 207 medline[sb]) and CINAHL EBSCO. The search for unpublished studies will include Google Scholar,
 208 government websites (i.e., National Institute of Nursing Research), hospice websites, the Library
 209 Network of Western Switzerland and WorldCat. We will also contact researchers who have recently
 210 published a paper on this topic, to make sure we are not missing on some unpublished work that could
 211 be included in this review. Finally, the reference list of all studies selected for critical appraisal will be
 212 screened for additional studies.

213 Study selection

214 As recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
 215 (PRISMA)⁴³, following the search, all identified citations will be collated and uploaded into EndNote X8
 216 /2016 (Clarivate Analytics, PA, USA) and duplicates removed. Titles and abstracts will then be screened
 217 by two independent reviewers (FTL & ASR) for assessment against the inclusion criteria for the review
 218 with the free software Rayyan QCRI that allows blinded assessment.⁴⁹ The full text of selected citations
 219 will be assessed in detail against the inclusion criteria by two independent reviewers (FTL & ASR).
 220 Reasons for exclusion of full text studies that do not meet the inclusion criteria will be recorded and
 221 reported in the systematic review. Any disagreements that arise between the reviewers at each stage
 222 of the study selection process will be resolved with a third reviewer (CMA) and through discussion. The
 223 results of the search will be reported in full in the final systematic review and presented in a Preferred
 224 Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram.⁵⁰

225 Assessment of Methodological Quality

226 Selected studies will be critically appraised by two independent reviewers for methodological quality
 227 using the standardized critical appraisal instrument from COSMIN methodology and instruments

228 (https://www.cosmin.nl/wp-content/uploads/COSMIN-RoB-checklist-V2-0-v17_rev3.pdf). “The result of
229 each study on a measurement property should be rated against the updated criteria for good
230 measurement properties. Each result is rated as either sufficient (+), insufficient (–), or indeterminate
231 (?)”.^{47 [p.28]} Any disagreements that arise will be resolved with a third reviewer and through discussion.
232 Following critical appraisal, the decision to exclude or not studies will be based on the COSMIN
233 recommendations.

234 Data Extraction

235 Data will be extracted from included studies, using the modified pilot tested data extraction form
236 (Appendix II) by two independent reviewers (FTL & ASR). The data extracted will include specific details
237 about the tests, populations, study methods and outcomes of significance to the review question and
238 specific objectives. Any disagreements that arise between the reviewers will be solved through
239 discussion, and if no consensus can be found a third reviewer (CMA) will be involved. Authors of papers
240 will be contacted to request missing or additional data where required.

241 Data Synthesis

242 The results will be quantitatively pooled or qualitatively summarized. They will be reported in a table
243 with the rating of the pooled or summarized results and the grading of the quality of evidence (high,
244 moderate, low, very low). “If possible, the results from different studies on one measurement property
245 should be statistically pooled in a meta-analysis. Pooled estimates of measurement properties can be
246 obtained by calculating weighted means (based on the number of participants included per study) and
247 95% confidence intervals”.^{47[p.31]} This meta-analysis will be performed by a statistician. The strategy for
248 meta-analysis will be based on the COSMIN guide. Where statistical pooling is not possible the findings
249 will be presented in narrative form including tables and figures to aid in data presentation where
250 appropriate.

251 Assessing Confidence

252 Grading of the quality will be based on a modified GRADE approach, where the quality of the evidence
253 is graded as high, moderate, low, or very low evidence.⁴⁵ “For evaluating measurement properties of
254 systematic reviews of PROMs, the following four factors should be taken into account: (1) risk of bias
255 (i.e. the methodological quality of the studies), (2) inconsistency (i.e. unexplained inconsistency of
256 results across studies), (3) imprecision (i.e. total sample size of the available studies), and (4)
257 indirectness (i.e. evidence from different populations than the population of interest in the review)”.^{47[p.32]}
258 A 'summary of findings' table will be created using GRADEPro GDT software.

259 Funding

260 This systematic review is part of a PhD thesis by the first author. The PhD candidate received a grant
261 from the Swiss Academy of the Medical Sciences (SAMS) and is supported by the Public health service
262 of the Canton de Vaud of Switzerland.

263 Conflicts of interest

264 There is no conflict of interest in this project.

265

ACCEPTED MANUSCRIPT

266 References

- 267 1. To TH, Greene AG, Agar MR, Currow DC. A point prevalence survey of hospital inpatients to define
268 the proportion with palliation as the primary goal of care and the need for specialist palliative care.
269 *Internal Medicine Journal*. 2011;41(5):430-3.
- 270 2. van Niekerk L, Raubenheimer PJ. A point-prevalence survey of public hospital inpatients with
271 palliative care needs in Cape Town, South Africa. *South Africa Medical Journal*. 2014;104(2):138-41.
- 272 3. Gott M, Frey R, Raphael D, O'Callaghan A, Robinson J, Boyd M. Palliative care need and management
273 in the acute hospital setting: a census of one New Zealand Hospital. *BMC Palliative Care*. 2013;12:15.
- 274 4. Zertuche-Maldonado T, Tellez-Villarreal R, Pascual A, Valdovinos-Chavez SB, Barragan-Berlanga AJ,
275 Sanchez-Avila MT, et al. Palliative Care Needs in an Acute Internal Medicine Ward in Mexico. *Journal*
276 *of Palliative Medicine*. 2018;21(2):163-8.
- 277 5. Meffert C, Rucker G, Hatami I, Becker G. Identification of hospital patients in need of palliative care-
278 -a predictive score. *BMC Palliat Care*. 2016;15:21.
- 279 6. Morin L, Aubry R, Frova L, MacLeod R, Wilson DM, Loucka M, et al. Estimating the need for palliative
280 care at the population level: A cross-national study in 12 countries. *Palliat Med*. 2016:1-11.
- 281 7. Murtagh FE, Bausewein C, Verne J, Groeneveld EI, Kaloki YE, Higginson IJ. How many people need
282 palliative care? A study developing and comparing methods for population-based estimates. *Palliat*
283 *Med*. 2014;28(1):49-58.
- 284 8. Office fédéral de la santé publique, Conférence suisse des directrices et directeurs cantonaux de la
285 santé. *Stratégie nationale en matière de soins palliatifs 2013-2015*. Berne: OFSP et CDS; 2012.
- 286 9. Pollock K. Is home always the best and preferred place of death? *BMJ*. 2015;351:h4855.
- 287 10. Burge F, Lawson B, Johnston G, Asada Y, McIntyre PF, Flowerdew G. Preferred and Actual Location
288 of Death: What Factors Enable a Preferred Home Death? *Journal of Palliative Medicine*. 2015.
- 289 11. Arnold E, Finucane AM, Oxenham D. Preferred place of death for patients referred to a specialist
290 palliative care service. *BMJ Supportive and Palliative Care*. 2015;5(3):294-6.
- 291 12. Murtagh FE, Addington-Hall J, Edmonds P, Donohoe P, Carey I, Jenkins K, et al. Symptoms in the
292 month before death for stage 5 chronic kidney disease patients managed without dialysis. *J Pain*
293 *Symptom Manage*. 2010;40(3):342-52.
- 294 13. Manitta V, Zordan R, Cole-Sinclair M, Nandurkar H, Philip J. The symptom burden of patients with
295 hematological malignancy: a cross-sectional observational study. *J Pain Symptom Manage*.
296 2011;42(3):432-42.
- 297 14. Penders YW, Onwuteaka-Philipsen B, Moreels S, Donker GA, Miccinesi G, Alonso TV, et al.
298 Differences in primary palliative care between people with organ failure and people with cancer: An
299 international mortality follow-back study using quality indicators. *Palliat Med*.
300 2018:269216318790386.
- 301 15. Rosenwax L, Spilsbury K, Arendts G, McNamara B, Semmens J. Community-based palliative care is
302 associated with reduced emergency department use by people with dementia in their last year of life:
303 A retrospective cohort study. *Palliat Med*. 2015;29(8):727-36.
- 304 16. Seow H, Brazil K, Sussman J, Pereira J, Marshall D, Austin PC, et al. Impact of community based,
305 specialist palliative care teams on hospitalisations and emergency department visits late in life and
306 hospital deaths: a pooled analysis. *BMJ*. 2014;348:g3496.
- 307 17. Dalgaard KM, Bergenholtz H, Nielsen ME, Timm H. Early integration of palliative care in hospitals:
308 A systematic review on methods, barriers, and outcome. *Palliative and Supportive Care*. 2014:1-19.
- 309 18. Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Barras M. Reducing potentially inappropriate
310 medications in palliative cancer patients: Evidence to support deprescribing approaches. *Support Care*
311 *Cancer*. 2014;22(4):1113-9.
- 312 19. Greer JA, Jackson VA, Meier DE, Temel JS. Early integration of palliative care services with standard
313 oncology care for patients with advanced cancer. *CA Cancer Journal for Clinicians*. 2013;63(5):349-63.
- 314 20. Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, et al. Effects of Early Integrated
315 Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. *J Clin Oncol*.
316 2017;35(8):834-41.

- 317 21. Afshar K, Geiger K, Muller-Mundt G, Bleidorn J, Schneider N. Generalist palliative care for non-
318 cancer patients : A review article. *Schmerz*. 2016.
- 319 22. Brown CR, Hsu AT, Kendall C, Marshall D, Pereira J, Prentice M, et al. How are physicians delivering
320 palliative care? A population-based retrospective cohort study describing the mix of generalist and
321 specialist palliative care models in the last year of life. *Palliat Med*. 2018;32(8):1334-43.
- 322 23. von Wartburg I. Soins palliatifs généraux. Recommandations et instruments de mise en œuvre.
323 Berne: Office fédéral de la santé publique OFSP, Conférence suisse des directrices et directeurs
324 cantonaux de la santé CDS & Palliative ch; 2015.
- 325 24. Gomez-Batiste X, Caja C, Espinosa J, Bullich I, Martinez-Munoz M, Porta-Sales J, et al. The Catalonia
326 World Health Organization demonstration project for palliative care implementation: quantitative and
327 qualitative results at 20 years. *J Pain Symptom Manage*. 2012;43(4):783-94.
- 328 25. World Health Organization. WHO Definition of Palliative Care2002: retrieved from
329 [<https://www.who.int/cancer/palliative/definition/en/>].
- 330 26. Boyd K, Murray SA. Recognising and managing key transitions in end of life care. *BMJ*.
331 2010;341:c4863.
- 332 27. Mitchell H, Noble S, Finlay I, Nelson A. Defining the palliative care patient: its challenges and
333 implications for service delivery. *BMJ Supportive Palliative Care*. 2013;3(1):46-52.
- 334 28. Van Mechelen W, Aertgeerts B, De Ceulaer K, Thoosen B, Vermandere M, Warmenhoven F, et al.
335 Defining the palliative care patient: a systematic review. *Palliat Med*. 2013;27(3):197-208.
- 336 29. Glare P, Plakovic K, Schloms A, Egan B, Epstein AS, Kelsen D, et al. Study using the NCCN guidelines
337 for palliative care to screen patients for palliative care needs and referral to palliative care specialists.
338 *Journal of the National Comprehensive Cancer Network*. 2013;11(9):1087-96.
- 339 30. Lamba S. Early goal-directed palliative therapy in the emergency department: a step to move
340 palliative care upstream. *Journal of Palliative Medicine*. 2009;12(9):767.
- 341 31. Richardson P, Greenslade J, Shanmugathasan S, Doucet K, Widdicombe N, Chu K, et al. PREDICT: a
342 diagnostic accuracy study of a tool for predicting mortality within one year: who should have an
343 advance healthcare directive? *Palliat Med*. 2015;29(1):31-7.
- 344 32. Boland JW, Reigada C, Yorke J, Hart SP, Bajwah S, Ross J, et al. The Adaptation, Face, and Content
345 Validation of a Needs Assessment Tool: Progressive Disease for People with Interstitial Lung Disease.
346 *Journal of Palliative Medicine*. 2016;19(5):549-55.
- 347 33. Cardona-Morrell M, Hillman K. Development of a tool for defining and identifying the dying patient
348 in hospital: Criteria for Screening and Triaging to Appropriate aLternative care (CrisTAL). *BMJ*
349 *Supportive and Palliative Care*. 2015;5(1):78-90.
- 350 34. Thomas K, Noble B. Improving the delivery of palliative care in general practice: an evaluation of
351 the first phase of the Gold Standards Framework. *Palliat Med*. 2007;21(1):49-53.
- 352 35. Highet G, Crawford D, Murray SA, Boyd K. Development and evaluation of the Supportive and
353 Palliative Care Indicators Tool (SPICT): a mixed-methods study. *BMJ Supportive and Palliative Care*.
354 2014;4(3):285-90.
- 355 36. Gomez-Batiste X, Martinez-Munoz M, Blay C, Amblas J, Vila L, Costa X, et al. Identifying patients
356 with chronic conditions in need of palliative care in the general population: development of the
357 NECPAL tool and preliminary prevalence rates in Catalonia. *BMJ Supportive and Palliative Care*.
358 2013;3(3):300-8.
- 359 37. Maas EA, Murray SA, Engels Y, Campbell C. What tools are available to identify patients with
360 palliative care needs in primary care: a systematic literature review and survey of European practice.
361 *BMJ Supportive and Palliative Care*. 2013;3(4):444-51.
- 362 38. Walsh R, Mitchell G, Francis L, van Driel L. What diagnostic tools exist for the early identification
363 of palliative care patients in general practice: a systematic review. *J Palliat Care*. 2015;31(2):118-23.
- 364 39. Thoosen B, Engels Y, van Rijswijk E, Verhagen S, van Weel C, Groot M, et al. Early identification
365 of palliative care patients in general practice: development of RADboud indicators for Palliative Care
366 Needs (RADPAC). *The British Journal of General Practice*. 2012;62(602):e625-31.

- 367 40. Grbich C, Maddocks I, Parker D, Brown M, Willis E, Piller N, et al. Identification of patients with
368 noncancer diseases for palliative care services. *Palliative and Supportive Care*. 2005;3(1):5-14.
- 369 41. Rainone F, Blank A, Selwyn PA. The early identification of palliative care patients: preliminary
370 processes and estimates from urban, family medicine practices. *Am J Hosp Palliat Care*.
371 2007;24(2):137-40.
- 372 42. McDaid P. A quick guide to identifying patients for supportive and palliative care. NHS; 2011.
- 373 43. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement
374 for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions:
375 explanation and elaboration. *PLoS Medicine*. 2009;6(7):e1000100.
- 376 44. Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, et al. COSMIN guideline
377 for systematic reviews of patient-reported outcome measures. *Qual Life Res*. 2018;27(5):1147-57.
- 378 45. Mokkink LB, de Vet HCW, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, et al. COSMIN Risk of Bias
379 checklist for systematic reviews of Patient-Reported Outcome Measures. *Qual Life Res*.
380 2018;27(5):1171-9.
- 381 46. Terwee CB, Prinsen CAC, Chiarotto A, de Vet HC, Bouter LM, Alonso J, et al. COSMIN methodology
382 for assessing the content validity of PROMs. Amsterdam; 2018.
- 383 47. Mokkink LB, Prinsen CAC, Patrick DL, J. A, Bouter LM, De Vet HC, et al. COSMIN methodology for
384 systematic reviews of Patient-Reported Outcome Measures (PROMs). Amsterdam; 2018.
- 385 48. Terwee CB, Jansma EP, Riphagen, II, de Vet HC. Development of a methodological PubMed search
386 filter for finding studies on measurement properties of measurement instruments. *Quality of Life in*
387 *Research*. 2009;18(8):1115-23.
- 388 49. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for
389 systematic reviews. *Systematic Reviews*. 2016;5(1):210.
- 390 50. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items
391 for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Medicine* 6(7): e1000097

392

393 Appendices

394 Appendix I: Search Strategy

395 Overview of the Medline Ovid SP search strategy

396 (exp palliative care/ OR terminal care/ OR exp terminally ill/ OR exp palliative medicine/ OR exp hospice
 397 and palliative care nursing/ OR (palliative OR "terminally ill" OR (terminal ADJ1 (care OR disease* OR
 398 patient*))).ab,ti,kf.) AND (exp patient selection/ OR exp transitional care/ OR referral and consultation/
 399 OR needs assessment/ OR (identification OR identify OR identifying OR referral OR (patient* ADJ3
 400 selection*) OR (transition* ADJ3 care) OR (assessment* ADJ6 (need OR needs))).ab,ti,kf.) AND
 401 (surveys and questionnaires/ OR (tool OR tools OR questionnaire* OR instrument OR instruments OR
 402 scale OR scales OR (surprise* ADJ3 question*) OR "gold standards framework" OR "gold standard
 403 framework" OR NECPAL OR SPICT OR RADPAC OR HR-PRO OR NAT OR PC-NAT OR GSF OR
 404 CriSTAL OR SPICT OR DanPaCT OR P-caREs).ab,ti,kf.)

ACCEPTED MANUSCRIPT

405 Appendix II: Data Extraction Instrument

406

| | |
|-----|---|
| 407 | Data extraction form for studies of measurement properties |
| 408 | |
| 409 | Citation Details |
| 410 | Authors: |
| 411 | Title: |
| 412 | Journal: |
| 413 | Year: |
| 414 | Issue: |
| 415 | Volume: |
| 416 | Pages: |
| 417 | Study details |
| 418 | Study design: |
| 419 | Instrument(s) assessed (sub-scales if applicable): |
| 420 | Construct assessed: |
| 421 | Country (language) in which instrument assessed: |
| 422 | Mode of administration (e.g. online, paper-based, etc.): |
| 423 | Setting/Context: |
| 424 | Participant Characteristics (study inclusion/exclusion information): |
| 425 | Description of main results (measurement properties) for each instrument: |
| 426 | Reviewer comments: |

427

428

429